Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) Induction Followed by HDT With ASCT and Maintenance Treatment With Velcade for Newly Diagnosed MM

NCT00378755 is registered in ClinicalTrials.gov with Korean Multiple Myeloma Working Party as lead sponsor.

NCT NCT00378755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00378755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) Induction Followed by HDT With ASCT and Maintenance Treatment With Velcade for Newly Diagnosed MM
Lead sponsor
Korean Multiple Myeloma Working Party
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2006
Completion date
July 31, 2008
Enrollment
62
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma